<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        42-29-97
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PUREGON 50 I.U AMP +SOLVENT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FOLLITROPIN BETA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        96.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ORGANON" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03GA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:8.7pt">Puregon solution for injection contains follitropin beta, a hormone known as follicle-stimulating hormone (FSH).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.7pt">FSH belongs to the group of gonadotrophins, which play an important role in human fertility and reproduction. In women, FSH is needed for the growth and development of follicles in the ovaries. Follicles are small round sacs that contain the egg cells. In men, FSH is needed for the production of sperm.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Puregon is used to treat infertility in any of the following situations:</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Women</p><p style="margin-left:5.9pt; margin-right:8.7pt">In women who do not ovulate and do not respond to treatment with clomifene citrate, Puregon can be used to cause ovulation.</p><p style="margin-right:6.75pt">In women undergoing assisted reproduction techniques, including <em>in vitro </em>fertilisation (IVF) and other methods, Puregon can bring about the development of multiple follicles.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Men</p><p style="margin-left:5.9pt; margin-right:8.75pt">In men who are infertile due to lowered hormone levels, Puregon can be used for the production of sperm.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not use Puregon</p><p><strong>If you:</strong></p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are allergic to follitropin beta or any of the other ingredients of Puregon (listed in section 6)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have a tumour of the ovary, breast, uterus, testis or brain (pituitary gland or hypothalamus)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have heavy or irregular vaginal bleeding where the cause is unknown</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ovaries that do not work because of a condition called primary ovarian failure</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ovarian cysts or enlarged ovaries not caused by polycystic ovarian syndrome (PCOS)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have malformations of the sexual organs which make a normal pregnancy impossible</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have fibroid tumours in the uterus which make a normal pregnancy impossible</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are a man and are infertile because of a condition called primary testicular failure.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Warnings and precautions</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p>Talk to your doctor before using Puregon if you:</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have had an allergic reaction to certain antibiotics (neomycin and/or streptomycin)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have uncontrolled pituitary gland or hypothalamic problems</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have an underactive thyroid gland (hypothyroidism)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have adrenal glands that are not working properly (adrenocortical insufficiency)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have high prolactin levels in the blood (hyperprolactinemia)</p><p style="margin-left:34.2pt; margin-right:9.55pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have any other medical conditions (for example, diabetes, heart disease, or any other long-term disease).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>If you are a woman:</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p>Ovarian hyperstimulation syndrome (OHSS)</p><p style="margin-left:5.9pt; margin-right:6.35pt">Your doctor will check the effects of the treatment regularly to be able to choose the correct dose of Puregon from day to day. You may regularly have ultrasound scans of the ovaries. Your doctor may also check blood hormone levels. This is very important since too high a dose of FSH may lead to rare but serious complications in which the ovaries are overly stimulated and the growing follicles become larger than normal. This serious medical condition is called ovarian hyperstimulation syndrome (OHSS). In rare cases, severe OHSS may be life-threatening. OHSS causes fluid to build up suddenly in your stomach and chest areas and can cause blood clots to form. Call your doctor right away if you notice severe abdominal swelling, pain in the stomach area (abdomen), feeling sick (nausea), vomiting, sudden weight gain due to fluid buildup, diarrhoea, decreased urine output or trouble breathing (see also section 4 on Possible side effects).</p><p style="margin-right:8.75pt">&agrave; Regular monitoring of the response to FSH-treatment helps to prevent ovarian overstimulation. Contact your doctor immediately if you are experiencing stomach pains, also if this occurs some days after the last injection has been given.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Multiple Pregnancy or birth defects</p><p style="margin-left:5.9pt; margin-right:8.7pt">After treatment with gonadotrophin preparations, there is an increased chance of having multiple pregnancies, even when only one embryo is transferred into the uterus. Multiple pregnancies carry an increased health risk for both the mother and her babies around the time of birth. Furthermore, multiple pregnancies and characteristics of the patients undergoing fertility treatment (e.g. age of the female, sperm characteristics, genetic background of both parents) may be associated with an increased risk of birth defects.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Pregnancy complications</p><p style="margin-left:5.9pt; margin-right:8.75pt">There is a slightly increased risk of a pregnancy outside the uterus (an ectopic pregnancy). Therefore, your doctor should perform an early ultrasound examination to exclude the possibility of pregnancy outside the uterus.</p><p>In women undergoing fertility treatment there may be a slightly higher chance of a miscarriage.</p><p>&nbsp;</p><p>Blood clot (Thrombosis)</p><p style="margin-left:5.9pt; margin-right:8.75pt">Treatment with Puregon, just as pregnancy itself, may increase the risk of having a blood clot (thrombosis). Thrombosis is the formation of a blood clot in a blood vessel.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify">Blood clots can lead to serious medical conditions, such as:</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blockage in your lungs (pulmonary embolus)</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stroke</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->heart attack</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blood vessel problems (thrombophlebitis)</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a lack of blood flow (deep venous thrombosis) that may result in a loss of your arm or leg.</p><p style="margin-left:0in">&nbsp;</p><p style="text-align:justify">Please discuss this with your doctor, before starting treatment, especially:</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you already know you have an increased chance of having thrombosis</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you, or anyone in your immediate family, have ever had a thrombosis</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are severely overweight.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Ovarian torsion</p><p style="margin-left:5.9pt; margin-right:6.75pt">Ovarian torsion has occurred after treatment with gonadotropins including Puregon. Ovarian torsion is the twisting of an ovary. Twisting of the ovary could cause the blood flow to the ovary to be cut off.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:justify">Before starting to use this medicine, tell your doctor if you:</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had ovarian hyperstimulation syndrome OHSS</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->are pregnant or think that you may be pregnant</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had stomach (abdominal) surgery</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have ever had a twisting of an ovary</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have past or current cysts in your ovary or ovaries.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Ovarian and Other Reproductive System Tumours</p><p style="margin-left:5.9pt; margin-right:23.0pt; text-align:justify">There have been reports of ovarian and other reproductive system tumors in women who have had infertility treatment. It is not known if treatment with fertility medicines increases the risk of these tumors in infertile women.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Other medical conditions</p><p style="text-align:justify">In addition, before starting to use this medicine, tell your doctor if you:</p><p style="margin-left:34.2pt; margin-right:0in; text-align:justify; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->have been told by a doctor that pregnancy would be dangerous for you.</p><p style="margin-left:0in">&nbsp;</p><p style="text-align:justify"><em>If you are a man:</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p>Men with too much FSH in their blood</p><p style="margin-left:5.9pt; margin-right:8.75pt">Increased FSH blood levels are a sign of damage to the testicles. Puregon is usually not effective in such cases. To check the effects of treatment, your doctor may ask you for a semen sample to be analysed, four to six months after the start of treatment.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Other medicines and Puregon</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:8.7pt">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.35pt; text-align:justify">If Puregon is used in a combination with clomifene citrate, the effect of Puregon may be increased. If a GnRH agonist (a medicine used to prevent early ovulation) has been given, higher doses of Puregon may be needed.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:5.3pt">Ask your doctor or pharmacist for advice before taking any medicine. You should not use Puregon if you are already pregnant, or think you might be pregnant.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:16.4pt">Puregon may affect milk production. It is unlikely that Puregon is passed into breast milk. If you are breast-feeding, tell your doctor before using Puregon.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Driving and using machines</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p>Puregon is unlikely to affect your ability to drive or use machines.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Important information about some of the ingredients of Puregon</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:38.75pt">This medicinal product contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Children</p><p>There is no relevant use of PUREGON in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Dosage in women</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:8.75pt">Your doctor will decide on your starting dose. This dose may be adjusted during your treatment period. Further details on the treatment schedule are given below.</p><p style="margin-right:5.3pt">There are large differences between women in the response of the ovaries to FSH, which makes it impossible to set a dosage schedule which is suitable for all patients. To find the right dosage, your doctor will check your follicle growth by means of ultrasound scanning, and measurement of the amount of oestradiol (female sex hormone) in the blood.</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Women who are not ovulating</em></p><p style="margin-left:34.2pt; margin-right:9.0pt">A starting dose is set by your doctor. This dose is continued for at least seven days. If there is no ovarian response, the daily dose will then be gradually increased until follicle growth and/or plasma oestradiol levels indicate a proper response. The daily dose is then maintained until a follicle of proper size is present. Usually, 7 to 14 days of treatment are sufficient. Puregon treatment is then stopped and ovulation will be induced by giving human chorionic gonadotrophin (hCG).</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Medically assisted reproduction programs, for instance IVF</em></p><p style="margin-left:34.2pt; margin-right:7.85pt">A starting dose is set by your doctor. This dose is continued for at least the first four days. After this, your dose may be adjusted, based upon your ovarian response. When a sufficient number of follicles of proper size are present, the final phase of maturation of the follicles is induced by giving hCG. Retrieval of the egg(s) is performed 34-35 hours later.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Dosage in men</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:7.85pt">Puregon is usually prescribed at a dose of 450 IU per week, mostly in 3 dosages of 150 IU, in combination with another hormone (hCG), for at least 3 to 4 months. The treatment period equals the development time of sperm and the time in which improvement can be expected. If your sperm production has not started after this period, your treatment may carry on for at least 18 months.</p><p>&nbsp;</p><p>How are the injections given</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:11.3pt">The very first injection of Puregon should only be given in the presence of a doctor or nurse. Injections may be given slowly into a muscle (for instance in the buttock, upper leg or upper arm) or under the skin (in the lower stomach, for example).</p><p>When given into a muscle the injection should be given by the doctor or nurse.</p><p style="margin-left:5.9pt; margin-right:23.85pt; text-align:justify">When given under the skin the injection may, in some cases, be given by yourself or your partner. Your doctor will tell you when and how to do this. If you inject yourself with Puregon, follow the instructions for use in the next section, to give Puregon properly and with minimal discomfort.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Instructions for use</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p><em>Step 1 - Preparing the syringe</em></p><p>You should use sterile disposable syringes and needles for the administration of Puregon. The volume of the syringe should be small enough so that the prescribed dose can be given with reasonable accuracy.</p><p style="margin-right:7.4pt">Puregon solution for injection comes in a glass vial. Do not use the solution if it contains particles or is not clear. First, you should remove the flip-off cap of the vial. Place a needle on a syringe and pierce the needle through the rubber stopper of the vial (a). Draw the solution up into the syringe (b), and replace the needle with an injection needle (c). Finally hold the syringe with the needle pointing upwards and gently tap the side to force any air bubbles up to the top; then squeeze the plunger until all the air has been expelled, and only Puregon solution is left in the syringe (d). If necessary, the plunger may be squeezed further, to adjust the volume to be administered.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:323.5pt;
 height:102pt'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><!--[if !vml]--><img width="431" height="136" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><!--[endif]--></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Step 2 - The injection site</em></p><p style="margin-left:5.9pt; margin-right:11.25pt">The best site for an injection under the skin is in the lower stomach around the navel (e) where there is a lot of loose skin and layers of fatty tissue. You should vary the injection site a little with each injection.</p><p>It is possible to inject in other areas. Your doctor or nurse will tell you where to inject.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Step 3 - Preparing the area</em></p><p>A few taps at the injection site will stimulate tiny nerve endings and help reduce discomfort when the needle goes in. Wash your hands and swab the injection site with disinfectant (for example chlorohexidine 0.5%) to remove any surface bacteria. Clean about two inches around the point where the needle will go in and let the disinfectant dry for at least one minute before you proceed.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Step 4 - Inserting the needle</em></p><p style="margin-left:5.9pt; margin-right:12.2pt">Pinch the skin a little. With the other hand, insert the needle at an angle of 90 degrees into the skin&rsquo;s surface, as shown in the picture (f).</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:152.5pt;height:102pt'>
 <v:imagedata src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><!--[if !vml]--><img width="203" height="136" src="file:///C:/Users/albalawi/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /><!--[endif]--></p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Step 5 - Checking the correct needle position</em></p><p style="margin-left:5.9pt; margin-right:3.15pt">If the needle position is correct the plunger should be quite difficult to draw back. Any blood sucked back into the syringe means that the needle tip has penetrated a vein or artery. If this happens pull out the syringe, cover the injection site with a swab containing disinfectant and apply pressure; the site will stop bleeding in a minute or two. Do not use this solution. Start again with <em>Step 1 </em>using a new syringe, new needles and a new vial of Puregon<em>.</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p><em>Step 6 - Injecting the solution</em></p><p style="margin-left:5.9pt; margin-right:7.1pt">Depress the plunger <strong>slowly </strong>and steadily, so the solution is correctly injected and the skin tissues are not damaged.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Step 7 - Removing the syringe</em></p><p style="margin-left:5.9pt; margin-right:10.7pt">Pull the syringe out quickly and apply pressure to the injection site with a swab containing disinfectant. A gentle massage of the site - while still maintaining pressure - helps disperse the Puregon solution and relieve any discomfort.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:244.55pt">Any remaining solution should be discarded. Do not mix Puregon with any other medicines.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>If you use more Puregon than you should</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p>Tell your doctor immediately.</p><p style="margin-left:5.9pt; margin-right:4.65pt">Too high a dose of Puregon may cause hyperstimulation of the ovaries (OHSS). This may be noticed as pain in the stomach. If you are troubled by stomach pains, tell your doctor immediately. See also section 4 on possible side effects.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>If you forget to use Puregon</p><p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p>If you forget a dose do not use a double dose to make up for a missed dose.</p><p>&agrave; Contact your doctor.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p><p style="margin-left:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Serious side effects in women</p><p style="margin-left:5.9pt; margin-right:6.1pt">A complication with FSH treatment is hyperstimulation of the ovaries. Ovarian overstimulation may develop into a medical condition called <strong>ovarian hyperstimulation syndrome (OHSS)</strong>, which can be a serious medical problem. The risk can be reduced by careful monitoring of follicular development during treatment. Your doctor will do ultrasound scans of your ovaries to carefully monitor the number of maturing follicles. Your doctor may also check blood hormone levels. Pain in the stomach, feeling sick or diarrhoea are the first symptoms. In more severe cases symptoms may include enlargement of the ovaries, accumulation of fluid in the abdomen and/or chest (which may cause sudden weight gain due to fluid buildup) and the occurrence of blood clots in the circulation. See warnings and precautions in section 2.</p><p style="margin-right:6.1pt">&agrave; Contact your doctor immediately if you are experiencing stomach pains, or any of the other symptoms of ovarian hyperstimulation, also if this occurs some days after the last injection.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>If you are a woman:</em></p><p>Common side effects (may affect up to 1 in 10 people):</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Injection site reactions (such as bruising, pain, redness, swelling and itching)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Ovarian hyperstimulation syndrome (OHSS)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Pelvic pain</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Stomach pain and/or bloating</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breast complaints (including tenderness)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Diarrhoea, constipation or stomach discomfort</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Enlargement of the uterus</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Feeling sick</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hypersensitivity reactions (such as rash, redness, hives and itching)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Ovarian cysts or enlargement of the ovaries</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Ovarian torsion (twisting of the ovaries)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Vaginal bleeding</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people):</p><p style="margin-left:34.2pt; margin-right:6.1pt; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Blood clots (this may also occur in the absence of unwanted overstimulation of the ovaries, see warnings and precautions in section 2)</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:6.9pt">Pregnancy outside the uterus (an ectopic pregnancy), miscarriage and multiple pregnancies have also been reported. These side effects are not considered to be related to the use of Puregon, but to Assisted Reproductive Technology (ART) or subsequent pregnancy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>If you are a man:</em></p><p>Common side effects (may affect up to 1 in 10 people):</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Acne</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Injection site reactions (such as hardening and pain)</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Headache</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Rash</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Some breast development</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Testicular cyst</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Reporting of side effects</p><p style="margin-left:5.9pt; margin-right:6.1pt">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Storage by the pharmacist</p><p>Store at 2&deg;C &ndash; 8&deg;C (in a refrigerator). Do not freeze.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Storage by the patient</p><p>You have two options:</p><p style="text-indent:0in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store at 2&deg;C &ndash; 8&deg;C (in a refrigerator). Do not freeze.</p><p style="margin-left:5.9pt; margin-right:23.7pt; text-indent:0in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Store at or below 25&ordm;C (at room temperature) for a single period of not more than 3 months. Make a note of when you start storing the product out of the refrigerator.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Keep the vial(s) in the outer carton.</p><p>The contents of a vial should be used immediately after piercing the rubber stopper.</p><p style="margin-left:5.9pt; margin-right:13.8pt">Do not use Puregon after the expiry date which is stated on the label and carton after &#39;EXP&#39;. The expiry date refers to the last day of that month.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.7pt">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Puregon contains</p><p>The active substance is follitropin beta.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:6.1pt"><u>Puregon 50 IU/0.5 mL solution for injection: </u>Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in strength of 50 IU in 0.5 mL aqueous solution per vial.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.75pt"><u>Puregon 100 IU/0.5 mL solution for injection: </u>Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in strength of 100 IU in 0.5 mL aqueous solution per vial.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.75pt">The other ingredients are sucrose, sodium citrate, L-methionine and polysorbate 20 in water for injections. The pH may have been adjusted with sodium hydroxide and/or hydrochloric acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Puregon solution for injection (injection) is a clear, colourless liquid. It is supplied in a glass vial. It is available in packs of 1, 5 or 10 vials.
Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:280.5pt"><strong>Marketing Authorization Holder </strong>Merck Sharp &amp; Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU</p><p>United Kingdom</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Manufacturer</p><p style="margin-left:5.9pt; margin-right:382.4pt">N.V. Organon Kloosterstraat 6 5349 AB Oss The Netherlands</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2016
Version No. (02)

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="margin-left:0in; margin-right:0in; text-align:justify" dir="RTL">يحتوي محلول بيوريجون للحقن على مادة فوليتروبين بيتا المؤتلف&nbsp;، وهو هرمون يُعرَف بالهرمون&nbsp; المؤتلف المنبّه للجُرَيبات(FSH) .</p><p style="margin-left:0in; margin-right:0in; text-align:justify" dir="RTL">ينتمي هذا الهرمون إلى مجموعة الجونادوتروفين التي تلعب دورا مُهمًّ في الإنجاب والخصوبة عند الإنسان. بالنسبة للإناث ، يُعتبَر هذا الهرمون ضروريًّا لنمو و تطور الجُرَيبات المبيضيّة، التي تتخّذ شكل أكياس مستديرة وصغيرة، تحتوي على خلايا البويضات. أما بالنسبة إلى الرجال، فيُعتبَر هذا الهرمون ضروريّا لإنتاج &nbsp;الحيوانات المنوية.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُستخدم البيوريجون لمعالجة العُقم في الحالات التالية:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الإناث</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">بالنسبة للإناث اللواتي لا يحدث لديهن اباضة أو لا تستجيب للعلاج بواسطة سترات الكلوميفين، يُمكن استخدام بيوريجون&nbsp; &nbsp;لتحفيز الإباضة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">بالنسبة للإناث اللواتي يخضعن لتقنيّات التلقيح بالمُساعدة، بما في ذلك الإخصاب في المختبر (IVF) (اطفال الانابيب) وطرق أخرى، يُمكن أن يُساهم بيوريجون في تكوين جُرَيبات متعدّدة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>للذكور</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">بالنسبة للذكر العاقر بسبب نقص هرموني ، يُمكن استخدام بيوريجون لإنتاج &nbsp;الحيوان المنوي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">لا تستخدم بيوريجون&nbsp; في الحالات التالية:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك حساسيّة من مادة فوليتروبين بيتا أو من أي مكوّن من المكوّنات الأخرى لبيوريجون (راجع البند ٦)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك ورم في المبيض، أو الثدي، أو الرحم، أو الخصية، أو الدماغ (الغدة النُخاميّة أو غدة تحت المهاد)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك نزيف مهبلي كثيف أو غير مُنتظِم بدون سبب معروف</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان المبيضان لديك لا يعملان بسبب حالة تُعرَف بفشل المبيض &nbsp;الأولي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك تكيس المبايض أو مبيضان منتفخان ولا يعود ذلك إلى متلازمة تكيّس المبايض (PCOS)&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك تشوّهات في الأعضاء التناسليّة، ما يجعل الحمل الطبيعي مستحيلاً</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك أورام ليفيّة في الرحم، ما يجعل الحمل الطبيعي مستحيلاً</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كنت رجلاً عاقرًا بسبب حالة تُعرَف بفشل الخصيتَيْن &nbsp;الأولي.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>التحذيرات والوقاية</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قبل استخدام بيورجون ، يُرجى التحدّث إلى الطبيب في الحالات التالية:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">&nbsp;- إذا كان لديك حساسيّة من بعض المُضادات الحيويّة (النيوميسين و/أو الاستربتوميسين)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">- إذا كان لديك مشاكل غير مسيطر عليها مرتبطة بغدة تحت المهاد أو الغدة النُخاميّة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">- إذا كان لديك قصور في الغدة الدرقيّة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">- إذا كانت الغدد الكظريّة لا تعمل بشكل جيّد (قصور قشرة الكظر)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">- إذا كان لدي مستوى مرتفع من البرولاكتين في الدم (فرط برولاكتين الدم)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">- إذا كان لديك حالات طبيّة أخرى (على سبيل المثال، داء السكري، أمراض القلب، أو أي مرض مزمن آخر)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>للإناث:</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>متلازمة فرط تحفيز المبيض </em></strong><strong><em>&nbsp;(OHSS)</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">سيُراقب الطبيب تأثيرات العلاج عليك بشكل مُنتظم لاختيار جرعة بيوريجون الملائمة، يومًا بعد يوم. كما قد تخضعين بشكل منتظم إلى فحص بالموجات فوق الصوتيّة للمبيضَيْن.&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قد يُراقب الطبيب أيضًا مستويات الهرمون في الدم. هذا مهمّ جدًّا لأنّ جرعة عالية جدًّا من الهرمون المنبّه للجُرَيب قد تؤدّي إلى مُضاعفات نادرة، إنّما خطرة، حيث يتمّ تحفيز المبيضَين بشكل مُفرط، ما يُعرَف بفرط تحفيز المبيض. في حالات نادرة، قد تهدّد حالة حادة من فرط تحفيز المبيض الحياة. فقد تُسبّب انحباس السوائل فجأةً في المعدة وفي الصدر وتخثّر الدم. يُرجى الاتصال بالطبيب فورًا في حال التعرّض لانتفاخ شديد في البطن، وألم في المعدة (البطن)، والشعور بالغثيان، أو التقيؤ، أو اكتساب مفاجئ للوزن بسبب تكدّس السوائل، أو الإسهال، أو انخفاض في كمية البول أو صعوبة في التنفّس (راجع أيضًا البند ٤ حول الآثار الجانبيّة المُحتملة)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- تُساهم المراقبة المنتظمة للاستجابة لعلاج بالهرمون المنبّه للجُرَيب (FSH) في الوقاية من فرط تحفيز المبيض</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- يُرجى الاتصال بالطبيب فورًا في حال التعرّض لألم في المعدة وفي حال ظهور هذا الألم بعد مرور أيّام على الحقنة الأخيرة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>الحمل المتعدّد أو التشوّهات الخلقيّة</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">بعد الخضوع لعلاج بالجونادوتروفين ، ثمة احتمال أكبر لحالات الحمل المتعدّد، حتى عند نقل جنين واحد إلى الرحم. وللحمل المتعدّد (مواليد التوائم) خطر متزايد على صحّة الأم وأطفالها عند الولادة. إلى ذلك، يُمكن ربط الحمل المتعدّد والمواصفات الخاصة للمرضى الذين يخضعون لعلاج العقم (مثلاً، سن المرأة، مواصفات &nbsp;الحيوان المنوي، الصفات الجينيّة للوالدَيْن) بازدياد نسبة التشوّهات الخلقيّة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>مضاعفات الحمل</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يرتفع خطر الحمل خارج الرحم (حمل منتبِذ) بشكل طفيف. لذا، على الطبيب أن يُجري فحصًا بالموجات فوق الصوتيّة مبكرًا لاستبعاد فرصة وجود حمل خارج الرحم.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">وبالنسبة إلى المرأة التي تخضع لعلاج العقم، يكون خطر التعرّض للإجهاض أعلى بقليل.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>تخثّر الدم (</em></strong><strong>تخثّر دموي</strong>)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">كما قد يؤدّي العلاج بواسطة بيوريجون، و الحمل أيضاً، على ازدياد خطر التعرّض لتخثّر دموي، أي تكوّن جلطة دمويّة في وعاءٍ دموي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قد يؤدّي التخثّر الدموي إلى حالات طبيّة خطرة، مثل:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- انسداد الرئتَيْن (صمّة رئويّة)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- سكتة دماغية</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- نوبة قلبيّة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- مشاكل في الأوعية الدمويّة (التهاب الوريد الخثاري)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- غياب التدفق الدموي (خثار وريدي عميق) ممّا قد يؤدّي إلى فقدان ذراع أو ساق.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُرجى مناقشة ذلك مع الطبيب قبل البدء بالعلاج، لا سيّما في الحالات التالية:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كنت تعرفين أنّك معرّضة لخطر أكبر بالإصابة بتخثّر</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كنت قد تعرّضت أو تعرّض أحد أفراد أسرتك لتخثّر</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كنت تعانين &nbsp;من الوزن الزائد بشكل كبير.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>&nbsp; </em></strong><strong><em>الالتواء المبيضي</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يعني الالتواء المبيضي التواء المبيضَيْن بسبب علاج بواسطة &nbsp;الجونادوتروفين، مثل البيوريجون ، ممّا قد يوقف التدفّق الدموي إلى المبيض.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قبل البدء باستخدام هذا الدواء، أطلعي طبيبك:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا ما تعرّضت في السابق لمتلازمة فرط تحفيز المبيضَيْن &nbsp;OHSS.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كنت حاملاً أو تظنّين أنك قد تكونين حاملاً.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا خضعت في السابق لعمليّة جراحيّة في المعدة (البطن)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا تعرّضت في السابق لالتواء مبيضي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا كان لديك، في الماضي أو في الحاضر، تكيسات في أحد المبيضَيْن أو في المبيضَيْن.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>&nbsp; </em></strong><strong><em>الأورام في المبيضَيْن وأورام أخرى في الجهاز التناسلي</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">تُشير تقارير إلى ظهور أورام في المبيضَيْن وأورام أخرى في <strong><em>الجهاز التناسلي</em></strong> لدى النساء اللواتي خضعن لعلاج ضدّ العقم. من غير المعروف إذا كان العلاج بواسطة أدوية الخصوبة يزيد من خطر الإصابة بهذه الأورام بالنسبة إلى النساء العقيمات.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>حالات طبيّة أخرى</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;قبل البدء باستخدام هذا الدواء، أطلعي الطبيب على ما يلي:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- إذا قال لك الطبيب إن الحمل يُشكّل خطرًا عليك</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>للذكور</strong><em>:</em></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>الذكور ومستوى الهرمون المنبّه للجُرَيب المرتفع جدًّا</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُشير مستوى الهرمون المنبّه للجُرَيب المرتفع في الدم إلى أضرار في الخصيتَيْن. وفي هذه الحالة، بيوريجون ليس فعالاً عادةً. وللتأكّد من آثار العلاج، قد يطلب منك الطبيب تحليل عيّنة من سائلك المنوي بعد مرور أربعة إلى ستّة أشهر على بداية العلاج.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong><em>استخدام أدوية أخرى مع بيوريجون</em></strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُرجى إطلاع الطبيب أو الصيدلي في حال كنت تتناول أدوية، أو قد تناولت منها مؤخّرًا أو قد تتناول أدوية أخرى.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">في حال استخدام بيوريجون بالتزامن مع سترات الكلوميفين، قد يتضاعف تأثير بيوريجون. وفي حال إعطاء الهرمون المطلق للجونادوتروفين GnRH (وهو دواء يُستخدَم لمنع الإباضة المبكرة)، قد تبرز الحاجة إلى جرعات أعلى من بيوريجون.</p><p style="margin-left:0in; margin-right:.25in; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الحمل والرضاعة</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">إسألي الطبيب أو الصيدلي للحصول على النصائح اللازمة قبل تناول أي دواء. . عليك عدم استخدام بيوريجون إذا كنت حاملاً أو تشكّين في أنّك قد تكونين حاملاً. قد يؤثّر بيوريجون على إنتاج الحليب. من المستبعد أن ينتقل إلى الحليب. &nbsp;إذا كنت تُرضعين، أخبري الطبيب قبل استخدام بيوريجون&nbsp; .</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>القيادة واستخدام الآليّات</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">من المستبعد أن يؤثّر بيوريجون على القدرة على القيادة أو استخدام الآليّات.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>معلومات هامّة حول بعض مكوّنات بيوريجون&nbsp; </strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يحتوي هذا الدواء على أقل من ١ مل مول من الصوديوم (٢٣ ملغم) في الحقنة الواحدة، أي شبه &quot;خالٍ من الصوديوم&quot;.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الأطفال:</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">ما من أوجه لاستخدام بيوريجون لدى الأطفال.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">استخدم هذا الدواء حسب وصفة الطبيب. عليك مراجعة الطبيب أو الصيدلي في حال لم تكن واثقاً.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الجرعة بالنسبة للإناث</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُحدّد الطبيب الجرعة الأوليّة التي يُمكن تكييفها في خلال فترة العلاج. أدناه تفاصيل إضافيّة حول الجدول الزمني للعلاج. ثمة فوارق كبيرة من إمرأة إلى أخرى في استجابة المبيض للهرمون المنبّه للجُرَيب، ممّا يجعل من المستحيل وضع جدول جرعات يكون ملائمًا للمرضى كافةً. ومن أجل التوصّل إلى الجرعة الملائمة، سيتأكّد الطبيب من نمو الجُرَيْب من خلال الفحص بالموجات فوق الصوتيّة وقياس كميّة الإستراديول (هرمون جنسي نسائي) في الدم.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><em>- المرأة التي لا يحدث لديها إباضة</em></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;يُحدّد الطبيب الجرعة الأوليّة التي تمتّد حتى سبعة أيام كحدّ أدنى. وفي غياب استجابة المبيض، يتمّ رفع الجرعة اليوميّة بشكل تدريجي حتى نمو الجُريب و/أو وصول مستويات الإستراديول في البلاسما لمستوى ملائم. عندئذ، يُحافَظ على الجرعة اليوميّة حتى وجود جُرَيب بالحجم الملائم. عادةً، يكون العلاج لمدّة ٧ إلى ١٤ يوماً كافياً. وبعد انقضاء هذه الفترة، يتمّ ايقاف العلاج بالبيوريجون وتحفيز الإباضة بواسطة الجونادوتروفين المشيمي البشري (hCG).</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><em>برامج التلقيح بالمساعدة، مثلا ً الإخصاب الصناعي (اطفال الانابيب)</em></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُحدّد الطبيب الجرعة الأوليّة التي تمتّد حتى الأيّام الأربعة الأولى. وبعد ذلك، يُمكن ضبط جرعتك، على أساس استجابة المبيضَيْن. عندما يتوفّر عدد كافٍ من الجُرَيبات من الحجم الملائم، يتمّ تحفيز المرحلة النهائيّة لنضوج الجُريبات من خلال إعطاء الجونادوتروفين المشيمي البشري ( hCG). ويتمّ استخراج البُويضة (البُويضات) بعد مرور ٣٤- ٣٥ ساعة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الجرعة بالنسبة للذكور</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">عادةً، يتمّ وصف بيوريجون بجرعة ٤٥٠ وحدة دوليّة في الأسبوع، وفي غالبيّة الحالات ٣ جرعات من ١٥٠ وحدة دوليّة، بالتزامن مع هرمون آخر (الجونادوتروفين المشيمي البشري) لمدّة ٣ إلى ٤ أشهر على الأقل. تُساوي فترة العلاج الوقت اللازم لنمو المني والوقت اللازم لتوقّع ظهور تحسّن. في حال لم يبدأ بعد إنتاج المني بعد انقضاء هذه الفترة، قد يستمرّ علاجك لمدّة ١٨ شهرا على الأقل.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>كيف تُعطى الحقن</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">ينبغي أن تعطى الحقنة الأولى من بيوريجون فقط في وجود طبيب أو ممرضة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">تعطى الحقن في العضل (كالردف، الفخذ و الذراع) ببطء أو تحت الجلد (على سبيل المثال ،في الجزء الأسفل من المعدة).</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">الحقن في العضل يجب أن يتم خلال طبيب أو ممرضة فقط.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">الحقن تحت الجلد يمكن أن يتم من خلال المريض أو شريكه.سيطلعك الطبيب على توقيت و طريقة الحقن. إذا قمت بحقن نفسك ببيوريجون اتبع تعليمات الاستخدام في البند التالي، لإعطاء بيوريجون بشكل صحيح وبأقل قدر من الانزعاج.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL"><strong>تعليمات الاستخدام</strong></p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة ١ - إعداد الحقنة</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">يجب إستخدام إبر وحقن معقّمّة يُتخلَّص منها بعد استعمالها عند إعطاء محلول بيوريجون. يجب أن يكون حجم الحقنة صغيرًا بما يكفي حرصًا على إعطاء الجرعة المطلوبة بالدقة المطلوبة.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">محلول بيوريجون للحقن متوّفر في فيال زجاجيّة. يجب عدم استخدام المحلول في حال احتوائه على جسيمات أو في حال لم يكن نقيًّا. أولاً، عليك إزالة سدادة الفيال. ضع إبرة على الحقنة واغرز الإبرة عبر السدادة المطاطيّة للفيال (a). إسحب المحلول في الحقنة (b) واستبدل الابرة بإبرة حقن (c). أخيرًا، أمسك بالحقنة مع الابرة نحو الأعلى وربّت برفق على جنبها لتوجيه أي فقّاعات هواء نحو الأعلى؛ ثمّ اضغط على مكبس الحقنة حتى اخراج الهواء بالكامل ولا يبقى إلا محلول بيوريجون في الحقنة (d). وفي حال الضرورة، يُمكن الضغط على المكبس بشكل أكبر من أجل ضبط الكميّة المراد إعطاؤها.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة ٢- موقع الحقنة</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">يُعتبر الجزء الأسفل من المعدة في محيط السرّة (e) الموقع الأفضل للحقن تحت الجلد، إذ يكون الجلد رخوًا ويكون هناك طبقات من الأنسجة الدهنيّة. عليك تبديل موقع الحقن قليلاً في كل مرة.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">من الممكن الحقن في أماكنَ أخرى. يُطلعك الطبيب أو الممرّضة على أماكن الحقن.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة ٣ - إعداد منطقة الحقن</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">يجب التربيت عدّة مرّات في موقع الحقن، ممّا من شأنه أن يُحفّز أطراف الأعصاب الصغيرة جدًّا ويُساهم في الحدّ من الانزعاج عند انغراز الابرة. يجب غسل اليدَيْن ومسح موقع الحقن بمطهّر (مثلاً، الكلورهيكسدين ٠.٥%) لإزالة أي بكتيريا على سطح الجلد. نظّف مساحة بوصتين تقريباً من حول النقطة حيث ستُغرز الإبرة ودع المطهّر يجفّ لدقيقة واحدة على الأقلّ قبل عمليّة الحقن.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة ٤ - غرز الإبرة</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">إقرص الجلد قليلاً. وبواسطة اليد الأخرى، إغرز الإبرة في زاوية من ٩٠درجة في سطح الجلد، كما هو معروض في الصورة (f).</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة ٥- التأكّد من أنّ الابرة في وضعيّة صحيحة</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">إذا كانت الإبرة في وضعيّة صحيحة، من الصعب جدًّا سحب المكبس. يعني وجود أي دم مسحوب في الحقنة أنّ رأس الإبرة انغرز في عرق أو شريان. وفي هذه الحال، أخرج الحقنة وغطِّ موقع الحقن بواسطة ماسحة تحتوي على مطهّر واضغط عليها؛ يتوقّف الموقع عن النزيف في غضون دقيقة أو دقيقتَيْن. لا تستخدم هذا المحلول. إبدأ مجدّدًا مع الخطوة ١، مع استخدام حقنة جديدة، وابر جديدة، و فيال جديدة من بيوريجون.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة&nbsp; ٦- حقن المحلول</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">أزِلْ الضغط عن المكبس ببطءٍ وبإحكامٍ من أجل حقن المحلول بشكلٍ صحيحٍ وعدم إلحاق الضرر بالأنسجة الجلديّة.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">الخطوة ٧- إزالة الحقنة</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">إسحب الحقنة بسرعة ومارس الضغط على موقع الحقن بواسطة ماسحة تحتوي على مطهّر. يُساعد التدليك&nbsp; برفق في الموقع - مع الابقاء على الضغط - في توزيع محلول بيوريجون والتخفيف من أي انزعاج.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">يجب التخلّص من أي محلول متبقٍّ.</p><p style="margin-right:1.0pt; text-align:justify" dir="RTL">لا تخلط البيوريجون مع أدوية أخرى.</p><p style="margin-left:1.0pt; text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>في حال حقن جرعة بيوريجون أعلى</strong><strong> </strong><strong>من الجرعة المفروضة</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">أطلع الطبيب فورًا.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قد تُسبّب جرعة عاليّة جدّا من بيوريجون تحفيزًا مفرطا للمبيضَيْن (OHSS) يُمكن ملاحظة ذلك من خلال ألم في المعدة. في حال عانيت ألمًا في المعدة، أطلع الطبيب على الفور. راجع أيضًا &nbsp;البند ٤ حول الآثار الجانبيّة المُحتملة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>في حال نسيت حقن بيوريجون&nbsp; </strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">في حال نسيت حقن جرعة واحدة، لا تحقن جرعتَيْن للتعويض عن الجرعة التي نسيتها.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُرجى الاتصال بالطبيب.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">إذا كان لديك أسئلة إضافيّة حول استخدام هذا الدواء، إطرحها على الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">على غرار الأدوية كلّها، يُمكن أن يُسبّب بيوريجون أعراض جانبيّة، وإن لم تكن تُصيب الجميع.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الأعراض </strong><strong>الجانبيّة الخطرة لدى الإناث</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">من مضاعفات العلاج بالهرمون المنبّه للجُرَيب، فرط تحفيز المبيضَيْن (OHSS).</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قد يُصبح فرط تحفيز المبيضَيْن حالةً طبيّة خطيرة جدًّا، لكن يُمكن الحدّ من خطر التعرّض لهذه الحالة من خلال مراقبة نمو الجريبات عن كثب خلال فترة العلاج. سيُجري الطبيب تصويرًا بالموجات فوق الصوتيّة للمبيضَيْن لمراقبة عدد الجُريبات في طور النضوج. كما قد يتأكّد الطبيب من مستويات الهرمون في الدم.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">وتشمل الأعراض الأولى لهذه الحالة الألم في المعدة، أو الشعور بالغثيان، أو الإسهال. وفي حالات أكثر حدّةً، قد تشمل الأعراض تضخّم المبيضَيْن، وتجمّع السوائل في البطن و/أو الصدر،(ممّا قد يُسبب اكتسابًا مفاجئًا للوزن بسبب تكدّس السوائل) وظهور الجلطات الدمويّة في الدورة الدموية. راجع التحذير والوقاية في البند ۲.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُرجى الاتّصال بالطبيب على الفور في حال تعرّضك لألم في المعدة أو لأي من الأعراض فرط تحفيز المبيضَيْن، وإن حدث ذلك بعد مرور بضعة أيّام على آخر حقنة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><em>للإناث:</em></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الأعراض </strong><strong>الجانبيّة </strong><strong>الشائعة</strong> (من المُحتمَل أن تُصيب مريضًا واحدًا من أصل ۱۰)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- صُداع</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- ردود فعل في موقع الحقنة (مثل التكدّم، والألم، والاحمرار، والانتفاخ، والحكاك)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- فرط تحفيز المبيضَيْن</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- ألم حوضي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- ألم و/أو انتفاخ في المعدة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الأعراض </strong><strong>الجانبيّة غير الشائعة</strong> (من المُحتمَل أن تُصيب مريضًا واحدًا من أصل ۱۰۰)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- ألم في الثديين (بما في ذلك الألم عند اللمس)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- الإسهال، أو الإمساك، أو الانزعاج في المعدة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- تضخّم الرحم</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- الشعور بالغثيان</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- ردود الفعل الحساسيّة (مثل الطفح الجلدي، والإحمرار، والشرى، والحكة)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- أكياس مبيضيّة وتضخّم حجم المبيضَيْن.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- التواء مبيضي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- نزيف مهبلي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الأعراض </strong><strong>الجانبيّة النادرة</strong> (من المُحتمَل أن تُصيب مريضًا واحدًا من أصل ۱۰۰۰):</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- جلطات دمويّة (قد يحدث ذلك في غياب فرط التحفيز المبيضي ، راجع &quot;التحذير والوقاية&quot; في البند ٢).</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">كما تمّ الابلاغ عن حالات حمل خارج الرحم (حمل منتبذ)، وإجهاض، وتعدّد الحمل. لا تُعتبر هذه الآثار الجانبيّة مرتبطة باستخدام بيوريجون، إنّما بتقنيّات التلقيح الصناعية(ART) &nbsp;أو الحمل الناتج عنها.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><em>&nbsp;</em></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>للذكور</strong>:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الأعراض </strong><strong>الجانبيّة الشائعة</strong> <strong>(من المُحتمَل أن تُصيب مريضاً واحداً من أصل ۱۰):</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- حبّ الشباب</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- ردود فعل في موقع الحقنة (مثل الألم أو التحجّر)</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- صُداع</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- طفح جلدي</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- نموّ الثدَيْن</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">- أكياس خصويّة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>الابلاغ عن </strong><strong>الأعراض </strong><strong>الجانبيّة</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">في حال لاحظت أعراض جانبيّة، يُرجى الاتصال بالطبيب أو الصيدلي. يشمل ذلك الآثار الجانبيّة المحتملة غير الواردة في هذه النشرة. يمكنك الإبلاغ عن الآثار الجانبية عن طريق &quot; المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء &quot; من خلال الابلاغ عن الآثار الجانبيّة، تساهم في إعطاء معلومات إضافيّة حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>التخزين لدى الصيدلي</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">يُحفظ في الثلاجة في درجة حرارة من ٢ إلى ۸ درجة مئوية. لا يجمّد.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>التخزين لدى المريض</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">أمامك خياران:</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">١. يُحفظ في الثلاجة في درجة حرارة من ٢ إلى ۸ درجة مئوية. لا يجمّد.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">٢. يُحفظ في درجة حرارة أقل من أو تعادل 25 درجة مئوية (درجة حرارة الغرفة). لفترة واحدة لا تتخطّى الثلاثة أشهر. يجب تدوين تاريخ بدء تخزين المستحضر خارج الثلاجة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;تًحفظ الفيال في العبوة الأصلية.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">ينبغي استخدام محتويات الفيال على الفور بعد اختراق السدادة المطاطية.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">لا تستخدم بيوريجون بعد انتهاء تاريخ الصلاحيّة الوارد على الملصق والعلبة بعد كلمة &quot;&#39;EXP&#39;&quot;. ويُشير تاريخ انتهاء الصلاحيّة إلى آخر يوم في الشهر المذكور.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;يُرجى عدم التخلّص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزليّة. إسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعد بحاجة إليها. من شأن هذه الإجراءات المساهمة في حماية البيئة.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">المادة الفاعلة : فوليتروبين بيتا</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">بيوريجون&nbsp; ٥٠ وحدة دوليّة / 5&cedil;0 مل، ، محلول للحقن: تحتوي كل فيال على مادة فوليتروبين بيتا الفاعلة، وهو هورمون يُعرَف بالهرمون المنبّه للجُرَيبات، بتركيز محلول مائي من ٥٠ وحدة دوليّة / 5&cedil;0 مل في كل فيال.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">بيوريجون&nbsp; 100 وحدة دوليّة / 5&cedil;0 مل ، محلول للحقن: تحتوي كل فيال على مادة فوليتروبين بيتا الفاعلة، وهو هورمون يُعرَف بالهرمون المنبّه للجُرَيبات، بتركيز محلول مائي من 100 وحدة دوليّة / 5&cedil;0 مل في كل فيال.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">المكوّنات الأخرى هي: سكروز، وسترات الصوديوم، وال-ميثيونين، وبوليسوربات ٢٠ و ماء للحقن. ويتمّ تعديل درجة الحموضة بواسطة هيدروكسيد الصوديوم و/أو حمض الهيدروكلوريك.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">محلول بيوريجون للحقن سائل نقي &nbsp;شفاف، متوّفر في فيال زجاجيّة، وتحتوي كل علبة على فيال واحدة أو ٥ أو ١٠ قوارير.</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">قد لا يتم تسويق كافة &nbsp;الأحجام .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p style="margin-left:1.0pt; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL"><strong>الشركة المالكة لحقوق التسويق:</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">ميرك شارب ودوم المحدودة،</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">طريق هيرتفورد، هوديسدون، هيرتفوردشاير</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">&nbsp;أي أن ١١ ٩ بي يو، المملكة المتحدة</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL">&nbsp;</p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL"><strong>الشركة الصانعة:</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">إن في أورجانون</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">كلوستيرسترات 6،</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">5349 إيه بي أوس،</p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL">هولندا<strong> </strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:justify" dir="RTL"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:1.0pt; text-align:right" dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمّت آخر مراجعة لهذه النشرة في مايو 2016الاصدار رقم (2)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Puregon 50 IU/0.5 ml solution for injection Puregon 100 IU/0.5 ml solution for injection 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Puregon 50 IU/0.5 ml solution for injection
One vial contains 50 IU recombinant follicle-stimulating hormone (FSH) in 0.5 mL aqueous solution.
This corresponds to a strength of 100 IU/mL. One vial contains 5 microgram of protein (specific
in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein). The solution for injection contains the active substance follitropin beta, produced by genetic engineering of a Chinese hamster ovary (CHO) cell line.


Puregon 100 IU/0.5 ml solution for injection
One vial contains 100 IU recombinant follicle-stimulating hormone (FSH) in 0.5 ml aqueous solution. This corresponds to strength of 200 IU/ml. One vial contains 10 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein). The solution for injection contains the active substance follitropin beta, produced by genetic engineering of a Chinese hamster ovary (CHO) cell line.

Excipient(s) with known effect:
This medicinal product contains less than 1 mmol sodium (23 mg) per injection, i.e. essentially ‘sodium-free’.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection). Clear and colourless solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p><em>In adult females:</em></p><p>Puregon is indicated for the treatment of female infertility in the following clinical situations:</p><p style="margin-left:34.2pt; margin-right:42.25pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Anovulation (including polycystic ovarian syndrome, PCOS) in women who have been unresponsive to treatment with clomifene citrate.</p><p style="margin-left:34.2pt; margin-right:11.3pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [e.g. <em>in vitro </em>fertilisation/embryo transfer (IVF/ET), gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)].</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>In adult males:</em></p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Deficient spermatogenesis due to hypogonadotrophic hypogonadism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:11.3pt">Treatment with Puregon should be initiated under the supervision of a physician experienced in the treatment of fertility problems.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:35.75pt">The first injection with Puregon should be performed under direct medical supervision. <u>Posology</u></p><p><em>Dosage in the female</em></p><p style="margin-left:5.9pt; margin-right:11.25pt">There are great inter- and intra-individual variations in the response of the ovaries to exogenous gonadotrophins. This makes it impossible to set a uniform dosage scheme. The dosage should, therefore, be adjusted individually depending on the ovarian response. This requires ultrasound assessment of follicular development. The concurrent determination of serum oestradiol levels may also be useful.</p><p style="margin-right:11.25pt">Based on the results of comparative clinical studies, it is considered appropriate to give a lower total dosage of Puregon over a shorter treatment period than generally used for urinary FSH, not only in order to optimise follicular development but also to reduce the risk of unwanted ovarian hyperstimulation (see section 5.1).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:5.75pt; text-align:justify">Clinical experience with Puregon is based on up to three treatment cycles in both indications. Overall experience with IVF indicates that in general the treatment success rate remains stable during the first four attempts and gradually declines thereafter.</p><p style="margin-left:34.2pt; margin-right:0in; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Anovulation</u></p><p style="margin-left:34.2pt; margin-right:8.75pt">A sequential treatment scheme is recommended starting with daily administration of 50 IU Puregon. The starting dose is maintained for at least seven days. If there is no ovarian response, the daily dose is then gradually increased until follicle growth and/or plasma oestradiol levels indicate an adequate pharmacodynamic response. A daily increase of oestradiol levels of</p><p style="margin-left:34.2pt; margin-right:8.7pt">40-100% is considered to be optimal. The daily dose is then maintained until pre-ovulatory conditions are reached. Pre-ovulatory conditions are reached when there is ultrasonographic evidence of a dominant follicle of at least 18 mm in diameter and/or when plasma oestradiol levels of 300-900 picograms/mL (1,000-3,000 pmol/L) are attained. Usually, 7 to 14 days of treatment is sufficient to reach this state. The administration of Puregon is then discontinued and ovulation can be induced by administering human chorionic gonadotrophin (hCG).</p><p style="margin-left:34.2pt; margin-right:8.7pt">If the number of responding follicles is too high or oestradiol levels increase too rapidly, i.e. more than a daily doubling for oestradiol for two or three consecutive days, the daily dose should be decreased.</p><p style="margin-left:34.2pt; margin-right:6.75pt">Since follicles of over 14 mm may lead to pregnancies, multiple pre-ovulatory follicles exceeding 14 mm carry the risk of multiple gestations. In that case hCG should be withheld and pregnancy should be avoided in order to prevent multiple gestations.</p><p style="margin-left:34.2pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Controlled ovarian hyperstimulation in medically assisted reproduction programs</u></p><p style="margin-left:34.2pt; margin-right:8.7pt">Various stimulation protocols are applied. A starting dose of 100-225 IU is recommended for at least the first four days. Thereafter, the dose may be adjusted individually, based upon ovarian response. In clinical studies it was shown that maintenance dosages ranging from 75-375 IU for six to twelve days are sufficient, although longer treatment may be necessary.</p><p style="margin-left:34.2pt; margin-right:8.75pt">Puregon can be given either alone, or, to prevent premature luteinisation, in combination with a GnRH agonist or antagonist. When using a GnRH agonist, a higher total treatment dose of Puregon may be required to achieve an adequate follicular response.</p><p style="margin-left:34.2pt; margin-right:8.7pt">Ovarian response is monitored by ultrasound assessment. The concurrent determination of serum oestradiol levels may also be useful. When ultrasound assessment indicates the presence of at least three follicles of 16-20 mm, and there is evidence of a good oestradiol response (plasma levels of about 300-400 picograms/mL (1,000-1,300 pmol/L) for each follicle with a diameter greater than 18 mm), the final phase of maturation of the follicles is induced by administration of hCG. Oocyte retrieval is performed 34-35 hours later.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Dosage in the male</em></p><p style="margin-left:5.9pt; margin-right:8.7pt">Puregon should be given at a dosage of 450 IU/week, preferably divided in 3 dosages of 150 IU, concomitantly with hCG. Treatment with Puregon and hCG should be continued for at least 3 to</p><p style="margin-right:6.75pt">4 months before any improvement in spermatogenesis can be expected. To assess the response, semen analysis is recommended 4 to 6 months after the beginning of treatment. If a patient has not responded after this period, the combination therapy may be continued; current clinical experience indicates that treatment for up to 18 months or longer may be necessary to achieve spermatogenesis.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Paediatric population</em></p><p style="margin-left:5.9pt; margin-right:22.75pt">There is no relevant use of Puregon in the paediatric population for the approved indication. <u>Method of administration</u></p><p style="margin-left:5.9pt; margin-right:8.75pt">To prevent painful injections and minimise leakage from the injection site Puregon should be slowly administered intramuscularly or subcutaneously. The subcutaneous injection site should be alternated to prevent lipoatrophy. Any unused solution should be discarded.</p><p style="margin-right:8.7pt">Subcutaneous injection of Puregon may be carried out by patient or partner, provided that proper instructions are given by the physician. Self-administration of Puregon should only be performed by patients who are well-motivated, adequately trained and with access to expert advice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For males and females
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Tumours of the ovary, breast, uterus, testis, pituitary or hypothalamus.
•	Primary gonadal failure

Additionally for females
•	Undiagnosed vaginal bleeding.
•	Ovarian cysts or enlarged ovaries, not related to polycystic ovarian syndrome (PCOS).
•	Malformations of the reproductive organs incompatible with pregnancy.
•	Fibroid tumours of the uterus incompatible with pregnancy.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p><em><u>Antibiotic hypersensitivity reactions</u></em></p><p style="margin-left:34.2pt; margin-right:24.15pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Puregon may contain traces of streptomycin and/or neomycin. These antibiotics may cause hypersensitivity reactions in susceptible persons.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Infertility evaluation before starting treatment</u></em></p><p style="margin-left:34.2pt; margin-right:10.7pt; text-indent:-28.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Before starting treatment, the couple&#39;s infertility should be assessed as appropriate. In particular, patients should be evaluated for hypothyroidism, adrenocortical insufficiency, hyperprolactinemia and pituitary or hypothalamic tumours, and appropriate specific treatment given.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>In females</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p><em><u>Ovarian Hyperstimulation Syndrome (OHSS)</u></em></p><p style="margin-left:5.9pt; margin-right:10.7pt">OHSS is a medical event distinct from uncomplicated ovarian enlargement. Clinical signs and symptoms of mild and moderate OHSS are abdominal pain, nausea, diarrhoea, mild to moderate enlargement of ovaries and ovarian cysts. Severe OHSS may be life-threatening. Clinical signs and symptoms of severe OHSS are large ovarian cysts, acute abdominal pain, ascites, pleural effusion, hydrothorax, dyspnoea, oliguria, haematological abnormalities and weight gain. In rare instances, venous or arterial thromboembolism may occur in association with OHSS. Transient liver function test abnormalities suggestive of hepatic dysfunction with or without morphologic changes on liver biopsy have also been reported in association with OHSS.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:4.65pt">OHSS may be caused by administration of human Chorionic Gonadotropin (hCG) and by pregnancy (endogenous hCG). Early OHSS usually occurs within 10 days after hCG administration and may be associated with an excessive ovarian response to gonadotropin stimulation. Late OHSS occurs more than 10 days after hCG administration, as a consequence of the hormonal changes with pregnancy. Because of the risk of developing OHSS, patients should be monitored for at least two weeks after hCG administration.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:7.1pt">Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS during or following treatment with Puregeon. For women having their first cycle of ovarian stimulation, for whom risk factors are only partially known, close observation for early signs and symptoms of OHSS is recommended.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:4.65pt">To reduce the risk of OHSS, ultrasonographic assessments of follicular development should be performed prior to treatment and at regular intervals during treatment. The concurrent determination of serum oestradiol levels may also be useful. In ART there is an increased risk of OHSS with 18 or more follicles of 11 mm or more in diameter. When there are 30 or more follicles in total it is advised to withhold hCG administration.</p><p>Depending on the ovarian response, the following measurements can be considered to reduce OHSS:</p><p style="margin-left:80.65pt; margin-right:48.15pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->withhold further stimulation with a gonadotropin for a maximum of 3 days (coasting);</p><p style="margin-left:80.65pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->withhold hCG and cancel the treatment cycle;</p><p style="margin-left:80.65pt; margin-right:16.5pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->administer a dose lower than 10,000 IU of urinary hCG for triggering final oocyte maturation, e.g. 5,000 IU urinary hCG or 250 micrograms rec-hCG (which is equivalent to approximately 6,500 IU of urinary hCG);</p><p style="margin-left:80.65pt; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cancel the fresh embryo transfer and cryopreserve embryos;</p><p style="margin-left:80.65pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->avoid administration of hCG for luteal phase support.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:16.5pt">If OHSS develops, standard and appropriate management of OHSS should be implemented and followed.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Multiple Pregnancy</u></em></p><p style="margin-left:5.9pt; margin-right:16.5pt">Multiple pregnancies and births have been reported for all gonadotropin treatments, including Puregon. Multiple gestation, especially high order, carries an increased risk of adverse maternal (pregnancy and delivery complications) and perinatal (low birth weight) outcomes.For anovulatory women undergoing ovulation induction, monitoring follicular development with transvaginal ultrasonography may aid in determining whether or not to continue the cycle in order to reduce the risk of multiple pregnancies. The concurrent determination of serum oestradiol levels may also be useful.The patients should be advised of the potential risks of multiple births before starting treatment.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>In women undergoing Assisted Reproduction Technologies (ART) procedures, the risk of a multiple pregnancy is mainly related to the number of embryos transferred. When used for an ovulation induction cycle, appropriate FSH dose adjustment(s) should prevent multiple follicle development.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Ectopic Pregnancy</u></em></p><p style="margin-left:5.9pt; margin-right:16.5pt">Infertile women undergoing ART have an increased incidence of ectopic pregnancies. Early ultrasound confirmation that a pregnancy is intrauterine is therefore important.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Spontaneous Abortion</u></em></p><p>Rates of pregnancy loss in women undergoing assisted reproduction techniques are higher than in the normal population.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Vascular Complications</u></em></p><p>Thromboembolic events, both in association with and separate from OHSS, have been reported following treatment with gonadotropins, including Puregon. Intravascular thrombosis, which may originate in venous or arterial vessels, can result in reduced blood flow to vital organs or the extremities. In women with generally recognised risk factors for thromboembolic events, such as a personal or family history, severe obesity or thrombophilia, treatment with gonadotropins, including Puregon, may further increase this risk. In these women the benefits of gonadotropin administration, including Puregon, need to be weighed against the risks. It should be noted, however, that pregnancy itself also carries an increased risk of thrombosis.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Congenital Malformations</u></em></p><p>The incidence of congenital malformations after ART may be slightly higher than after spontaneous conceptions. This is thought to be due to differences in parental characteristics (e.g., maternal age, sperm characteristics) and multiple gestations.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Ovarian Torsion</u></em></p><p>Ovarian torsion has been reported after treatment with gonadotropins, including Puregon. Ovarian torsion may be associated with other risk factors such as OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.</p><p style="margin-right:16.5pt">Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Ovarian and Other Reproductive System Neoplasms</u></em></p><p style="margin-left:5.9pt; margin-right:5.3pt">There have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple treatment regimens for infertility treatment. It is not established whether or not treatment with gonadotrophins increases the risk of these tumours in infertile women.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em><u>Other Medical Conditions</u></em></p><p style="margin-left:5.9pt; margin-right:7.85pt">Medical conditions that contraindicate pregnancy should also be evaluated before starting treatment with Puregon.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>In males</em></p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p><em><u>Primary Testicular Failure</u></em></p><p style="margin-left:5.9pt; margin-right:7.85pt">Elevated endogeneous FSH levels in men are indicative of primary testicular failure. Such patients are unresponsive to Puregon/hCG therapy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:5.3pt">Concomitant use of Puregon and clomifene citrate may enhance the follicular response. After pituitary desensitisation induced by a GnRH agonist, a higher dose of Puregon may be necessary to achieve an adequate follicular response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u></p><p style="margin-left:5.9pt; margin-right:5.3pt">Puregon is used in the treatment of women undergoing ovarian induction or controlled ovarian hyperstimulation in assisted reproduction programmes. In males Puregon is used in the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism. For posology and method of administration, see section 4.2.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Pregnancy</u></p><p style="margin-left:5.9pt; margin-right:7.85pt">The use of Puregon during pregnancy is not indicated. In case of inadvertent exposure during pregnancy, clinical data are not sufficient to exclude a teratogenic effect of recombinant FSH. However, to date, no particular malformative effect has been reported. No teratogenic effect has been observed in animal studies.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Breast-feeding</u></p><p style="margin-left:5.9pt; margin-right:7.85pt">There is no information available from clinical or animal studies on the excretion of follitropin beta in milk. It is unlikely that follitropin beta is excreted in human milk due to its high molecular weight. If follitropin beta would be excreted in human milk, it would be degraded in the gastrointestinal tract of the child. Follitropin beta may affect milk production.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Puregon has no or negligible influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:7.85pt">Clinical use of Puregon by the intramuscular or subcutaneous routes may lead to local reactions at the site of injection (3% of all patients treated). The majority of these local reactions are mild and transient in nature. Generalised hypersensitivity reactions been observed uncommonly (approximately 0.2% of all patients treated with follitropin beta).</p><p><em>&nbsp;</em></p><p><em>Treatment of females:</em></p><p style="margin-left:5.9pt; margin-right:8.75pt">In approximately 4% of the women treated with follitropin beta in clinical trials, signs and symptoms related to ovarian hyperstimulation syndrome (OHSS) have been reported (see section 4.4). Adverse reactions related to this syndrome include pelvic pain and/or congestion, abdominal pain and/or distension, breast complaints and ovarian enlargement.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.75pt">The table below lists the adverse reactions with follitropin beta reported in clinical trials in females, according to system organ class and frequency; common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to</p><p>&lt; 1/100).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:13.45pt; vertical-align:top; width:2.05in"><p style="margin-left:5.1pt; margin-right:0in"><strong>SOC</strong></p></td><td style="border-color:black; height:13.45pt; vertical-align:top; width:107.65pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>Frequency</strong></p></td><td style="border-color:black; height:13.45pt; vertical-align:top; width:148.8pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>Adverse reaction</strong></p></td></tr><tr><td style="border-color:black; height:13.45pt; vertical-align:top; width:2.05in"><p style="margin-left:3.3pt">Nervous system disorders</p></td><td style="height:13.45pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Common</p></td><td style="height:13.45pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt">Headache</p></td></tr><tr><td style="border-color:black; height:26.4pt; vertical-align:top; width:2.05in" rowspan="2"><p style="margin-left:3.3pt">Gastrointestinal disorders</p></td><td style="height:26.4pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Common</p></td><td style="height:26.4pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt; margin-right:47.45pt">Abdominal distension Abdominal pain</p></td></tr><tr><td style="height:52.3pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Uncommon</p></td><td style="height:52.3pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt; margin-right:44.65pt">Abdominal discomfort Constipation Diarrhoea</p><p style="margin-left:3.3pt">Nausea</p></td></tr><tr><td style="border-color:black; height:26.4pt; vertical-align:top; width:2.05in" rowspan="2"><p style="margin-left:3.3pt; margin-right:32.1pt">Reproductive system and breast disorders</p></td><td style="height:26.4pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Common</p></td><td style="height:26.4pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt">OHSS</p><p style="margin-left:3.3pt; margin-right:0in">Pelvic pain</p></td></tr><tr><td style="height:91.2pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Uncommon</p></td><td style="height:91.2pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt">Breast complaints1</p><p style="margin-left:3.3pt; margin-right:86.35pt">Metrorrhagia Ovarian cyst</p><p style="margin-left:3.3pt; margin-right:49.5pt">Ovarian enlargement Ovarian torsion Uterine enlargement Vaginal haemorrhage</p></td></tr><tr><td style="border-color:black; height:26.4pt; vertical-align:top; width:2.05in" rowspan="2"><p style="margin-left:3.3pt; margin-right:12.45pt">General disorders and administration site conditions</p></td><td style="height:26.4pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Common</p></td><td style="height:26.4pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt">Injection site reaction2</p></td></tr><tr><td style="height:26.4pt; vertical-align:top; width:107.65pt"><p style="margin-left:3.3pt">Uncommon</p></td><td style="height:26.4pt; vertical-align:top; width:148.8pt"><p style="margin-left:3.3pt; margin-right:18.55pt">Generalised hypersensitivity reaction3</p></td></tr></tbody></table><p style="margin-left:41.9pt; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Breast complaints include tenderness, pain and/or engorgement and nipple pain</p><p style="margin-left:41.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Local reactions at the site of injection include: bruising, pain, redness, swelling and itching</p><p style="margin-left:41.9pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Generalised hypersensitivity reaction include erythema, urticaria, rash and pruritus</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.7pt">In addition, ectopic pregnancy, miscarriage and multiple gestations have been reported. These are considered to be related to ART or subsequent pregnancy.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.7pt">In rare instances, thromboembolism has been associated with follitropin beta /hCG therapy as with other gonadotrophins.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><em>Treatment of males:</em></p><p style="margin-left:5.9pt; margin-right:13.8pt">The table below lists the adverse reactions with follitropin beta reported in a clinical trial in males (30 patients dosed), according to system organ class and frequency; common (&ge; 1/100 to &lt; 1/10).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:14.15pt; vertical-align:top; width:167.4pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>SOC</strong></p></td><td style="border-color:black; height:14.15pt; vertical-align:top; width:1.75in"><p style="margin-left:5.1pt"><strong>Frequency</strong>1</p></td><td style="border-color:black; height:14.15pt; vertical-align:top; width:150.0pt"><p style="margin-left:5.1pt; margin-right:0in"><strong>Adverse reaction</strong></p></td></tr><tr><td style="border-color:black; height:13.9pt; vertical-align:top; width:167.4pt"><p style="margin-left:5.1pt">Nervous system disorders</p></td><td style="height:13.9pt; vertical-align:top; width:1.75in"><p style="margin-left:5.1pt">Common</p></td><td style="height:13.9pt; vertical-align:top; width:150.0pt"><p style="margin-left:5.1pt">Headache</p></td></tr><tr><td style="border-color:black; height:27.35pt; vertical-align:top; width:167.4pt"><p style="margin-left:5.1pt; margin-right:32.25pt">Skin and subcutaneous tissue disorders</p></td><td style="height:27.35pt; vertical-align:top; width:1.75in"><p style="margin-left:5.1pt">Common</p></td><td style="height:27.35pt; vertical-align:top; width:150.0pt"><p style="margin-left:5.1pt; margin-right:120.95pt">Acne Rash</p></td></tr><tr><td style="border-color:black; height:28.55pt; vertical-align:top; width:167.4pt"><p style="margin-left:5.1pt; margin-right:20.8pt">Reproductive system and breast disorders</p></td><td style="height:28.55pt; vertical-align:top; width:1.75in"><p style="margin-left:5.1pt">Common</p></td><td style="height:28.55pt; vertical-align:top; width:150.0pt"><p style="margin-left:5.1pt; margin-right:72.35pt">Epididymal cyst Gynaecomastia</p></td></tr><tr><td style="border-color:black; height:26.9pt; vertical-align:top; width:167.4pt"><p style="margin-left:5.1pt; margin-right:30.45pt">General disorders and administration site conditions</p></td><td style="height:26.9pt; vertical-align:top; width:1.75in"><p style="margin-left:5.1pt">Common</p></td><td style="height:26.9pt; vertical-align:top; width:150.0pt"><p style="margin-left:5.1pt">Injection site reaction2</p></td></tr></tbody></table><p style="margin-left:39.85pt; margin-right:22.75pt; text-indent:-16.9pt"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Adverse reactions that are reported only once are listed as common because a single report raises the frequency above 1%.</p><p style="margin-left:40.1pt; text-indent:-17.05pt"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Local reactions at the site of injection include induration and pain.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p style="margin-left:5.9pt; margin-right:3.15pt">Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Saudi Arabia: </u></p><p style="text-align:justify">The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p style="text-align:justify">o Fax: +966-11-205-7662</p><p style="text-align:justify">o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p style="text-align:justify">o Toll free phone: 8002490000</p><p style="text-align:justify">o E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:justify">o Website: www.sfda.gov.sa/npc</p><p style="margin-left:45.0pt; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other GCC States: </u></p><p style="text-align:justify">Please contact the relevant competent authority.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:8.7pt">No data on acute toxicity of Puregon in humans is available, but the acute toxicity of Puregon and of urinary gonadotrophin preparations in animal studies has been shown to be very low. Too high a dosage of FSH may lead to hyperstimulation of the ovaries (see section 4.4).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:8.75pt">Pharmacotherapeutic group: sex hormones and modulators of the genital system, gonadotrophins; ATC code: G03G A06.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.7pt">Puregon contains a recombinant FSH. This is produced by recombinant DNA technology, using a Chinese hamster ovary cell line transfected with the human FSH subunit genes. The primary amino acid sequence is identical to that of natural human FSH. Small differences in the carbohydrate chain structure are known to exist.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Mechanism of Action</u></p><p style="margin-left:5.9pt; margin-right:8.7pt">FSH is indispensable in normal follicular growth and maturation, and gonadal steroid production. In the female the level of FSH is critical for the onset and duration of follicular development, and consequently for the timing and number of follicles reaching maturity. Puregon can thus be used to stimulate follicular development and steroid production in selected cases of disturbed gonadal function. Furthermore Puregon can be used to promote multiple follicular development in medically assisted reproduction programs [e.g. <em>in vitro </em>fertilisation/embryo transfer (IVF/ET), gamete intra- fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)]. Treatment with Puregon is generally followed by administration of hCG to induce the final phase of follicle maturation, resumption of meiosis and rupture of the follicle.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Clinical Efficacy and Safety</u></p><p style="margin-left:5.9pt; margin-right:6.75pt">In clinical studies comparing recFSH (follitropin beta) and urinary FSH for controlled ovarian stimulation in women participating in an assisted reproduction technology (ART) program and for ovulation induction (see tables 1 and 2 below), Puregon was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:22.75pt">For controlled ovarian stimulation, Puregon resulted in a higher number of oocytes retrieved at a lower total dose and with a shorter treatment period, when compared to urinary FSH.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-right:8.75pt">Table 1: Results of study 37,608 (randomized, group comparative clinical study comparing safety and efficacy of Puregon with urinary FSH in controlled ovarian stimulation).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:.45in; vertical-align:top; width:256.55pt"><p>&nbsp;</p></td><td style="border-color:black; height:.45in; vertical-align:top; width:85.45pt"><p style="margin-left:21.5pt; margin-right:21.35pt; text-indent:.95pt"><strong>Puregon (n = 546)</strong></p></td><td style="border-color:black; height:.45in; vertical-align:top; width:85.55pt"><p style="margin-left:21.5pt; margin-right:21.45pt; text-indent:5.15pt"><strong>u-FSH</strong><strong> </strong><strong>(n = 361)</strong></p></td></tr><tr><td style="border-color:black; height:19.45pt; vertical-align:top; width:256.55pt"><p style="margin-left:5.1pt; margin-right:0in">Mean no. of oocytes retrieved</p></td><td style="height:19.45pt; vertical-align:top; width:85.45pt"><p style="margin-left:27.65pt; margin-right:0in">10.84*</p></td><td style="height:19.45pt; vertical-align:top; width:85.55pt"><p style="text-align:center">8.95</p></td></tr><tr><td style="border-color:black; height:19.45pt; vertical-align:top; width:256.55pt"><p style="margin-left:5.1pt; margin-right:0in">Mean total dose (no. of 75 IU ampoules)</p></td><td style="height:19.45pt; vertical-align:top; width:85.45pt"><p style="margin-left:.3pt; margin-right:0in; text-align:center">28.5*</p></td><td style="height:19.45pt; vertical-align:top; width:85.55pt"><p style="text-align:center">31.8</p></td></tr><tr><td style="border-color:black; height:19.45pt; vertical-align:top; width:256.55pt"><p style="margin-left:5.1pt; margin-right:0in">Mean duration of FSH stimulation (days)</p></td><td style="height:19.45pt; vertical-align:top; width:85.45pt"><p style="margin-left:.3pt; margin-right:0in; text-align:center">10.7*</p></td><td style="height:19.45pt; vertical-align:top; width:85.55pt"><p style="text-align:center">11.3</p></td></tr></tbody></table><p>* Differences between the 2 groups were statistically significant (p&lt;0.05).</p><p style="margin-left:5.9pt; margin-right:7.25pt">&nbsp;</p><p style="margin-left:5.9pt; margin-right:7.25pt">For ovulation induction, Puregon resulted in a lower median total dose and shorter median duration of treatment when compared to urinary FSH.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Table 2: Results of study 37,609 (randomized, group comparative clinical study comparing safety and efficacy of Puregon with urinary FSH in ovulation induction).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="border-color:black; height:.45in; vertical-align:top; width:256.55pt"><p>&nbsp;</p></td><td style="border-color:black; height:.45in; vertical-align:top; width:85.45pt"><p style="margin-left:21.5pt; margin-right:21.35pt; text-indent:.95pt"><strong>Puregon (n = 105)</strong></p></td><td style="border-color:black; height:.45in; vertical-align:top; width:85.55pt"><p style="margin-left:24.3pt; margin-right:24.25pt; text-indent:2.4pt"><strong>u-FSH</strong><strong> </strong><strong>(n = 66)</strong></p></td></tr><tr><td style="height:20.65pt; vertical-align:top; width:256.55pt"><p style="margin-left:5.1pt; margin-right:0in">Mean no. of follicles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3; 12 mm</p></td><td style="height:20.65pt; vertical-align:top; width:85.45pt"><p style="margin-left:.3pt; margin-right:0in; text-align:center">3.6*</p></td><td style="height:20.65pt; vertical-align:top; width:85.55pt"><p style="text-align:center">2.6</p></td></tr><tr><td style="height:20.15pt; vertical-align:top; width:256.55pt"><p style="margin-left:133.35pt; margin-right:0in">&sup3; 15 mm</p></td><td style="height:20.15pt; vertical-align:top; width:85.45pt"><p style="margin-left:.1pt; margin-right:0in; text-align:center">2.0</p></td><td style="height:20.15pt; vertical-align:top; width:85.55pt"><p style="text-align:center">1.7</p></td></tr><tr><td style="border-color:black; height:19.7pt; vertical-align:top; width:256.55pt"><p style="margin-left:133.35pt; margin-right:0in">&sup3; 18 mm</p></td><td style="height:19.7pt; vertical-align:top; width:85.45pt"><p style="margin-left:.1pt; margin-right:0in; text-align:center">1.1</p></td><td style="height:19.7pt; vertical-align:top; width:85.55pt"><p style="text-align:center">0.9</p></td></tr><tr><td style="border-color:black; height:22.9pt; vertical-align:top; width:256.55pt"><p style="margin-left:5.1pt; margin-right:0in">Median total dose (IU)a</p></td><td style="height:22.9pt; vertical-align:top; width:85.45pt"><p style="margin-left:.15pt; margin-right:0in; text-align:center">750*</p></td><td style="height:22.9pt; vertical-align:top; width:85.55pt"><p style="text-align:center">1,035</p></td></tr><tr><td style="border-color:black; height:22.9pt; vertical-align:top; width:256.55pt"><p style="margin-left:5.1pt; margin-right:0in">Median duration of treatment (days)a</p></td><td style="height:22.9pt; vertical-align:top; width:85.45pt"><p style="margin-left:.3pt; margin-right:0in; text-align:center">10.0*</p></td><td style="height:22.9pt; vertical-align:top; width:85.55pt"><p style="text-align:center">13.0</p></td></tr></tbody></table><p>* Differences between the 2 groups were statistically significant (p&lt;0.05).</p><p>a</p><p style="margin-left:12.4pt">Restricted to women with ovulation induced (Puregon, n = 76; u-FSH, n = 42).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p style="margin-left:5.9pt; margin-right:7.25pt">After intramuscular or subcutaneous administration of Puregon, maximum concentrations of FSH are reached within about 12 hours. After intramuscular administration of Puregon, the maximum FSH concentrations are higher and reached earlier in men as compared to women. Due to the sustained release from the injection site and the elimination half-life of about 40 hours (ranging from 12 to</p><p>70 hours), FSH levels remain increased for 24-48 hours. Due to the relatively long elimination</p><p>half-life, repeated administration of the same dose will lead to plasma concentrations of FSH that are approximately 1.5-2.5 times higher than after single dose administration. This increase enables therapeutic FSH concentrations to be reached.</p><p>There are no significant pharmacokinetic differences between intramuscular and subcutaneous administration of Puregon. Both have an absolute bioavailability of approximately 77%.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p><u>Distribution, biotransformation and elimination</u></p><p style="margin-left:5.9pt; margin-right:7.25pt">Recombinant FSH is biochemically very similar to urinary human FSH and is distributed, metabolised, and excreted in the same way.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:9.25pt">-dose administration of Puregon to rats induced no toxicologically significant effects. In repeated-dose studies in rats (two weeks) and dogs (13 weeks) up to 100-fold the maximal human dose, Puregon induced no toxicologically significant effects. Puregon showed no mutagenic potential in the Ames test and in the <em>in vitro </em>chromosome aberration test with human lymphocytes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:246.25pt">Puregon solution for injection contains: Sucrose</p><p style="margin-right:388.25pt">Sodium citrate L-methionine Polysorbate 20</p><p>Water for injections.</p><p>The pH may have been adjusted with sodium hydroxide and/or hydrochloric acid.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:7.1pt">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3	years.

The contents of a vial should be used immediately after piercing of the rubber stopper.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:288.8pt">Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.</p><p>Keep the vial(s) in the outer carton.</p><p style="margin-left:5.9pt; margin-right:4.65pt">For patient convenience, Puregon may be stored at or below 30&ordm;C by the patient for a single period of not more than 3 months.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in"><strong>&nbsp;</strong></p><p style="margin-right:83.2pt">0.5 ml of solution in 3 ml vial (type I glass) with stopper (chlorobutyl rubber). Pack of 1, 5 or 10 vials.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use if the solution contains particles or if the solution is not clear.</p><p>The contents of a vial should be used immediately after piercing of the rubber stopper.</p><p style="margin-left:5.9pt; margin-right:10.7pt">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom

Manufacturer:
N.V. Organon, Kloosterstaat 6, 5349 AB Oss, The Netherlands

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2016 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>